TP53 and non-small cell lung carcinoma: As one of the most common mutations in NSCLC, TP53 alteration exhibited prognostic value in first-line tyrosine kinase inhibitor therapy20, postoperative adjuvant therapy21 and PD-1 blockade immunotherapy22.